Citic Private Equity
CITIC PE invests in China's New Journey Hospital
CITIC Private Equity (CITIC PE) has invested an undisclosed sum in New Journey Hospital Group, a Chinese cancer hospital operator.
PE investors to exit China's Happigo Home Shopping
Hony Capital, CITIC Private Equity and Sequoia Capital are set to exit Happigo Home Shopping, a Shenzhen-listed online and TV shopping subsidiary of Hunan TV.
PE-backed BeiGene gains 18% on debut after $158m IPO
BeiGene, a Chinese cancer drug developer backed by Hillhouse Capital and CITIC Private Equity, closed up 18% on its first day of trading on NASDAQ following a $158.4 million IPO.
CITIC PE-owned online finance platforms raise $65m
Maidai Licai and China Top Credit, two Chinese online finance platforms wholly-owned by CITIC Private Equity, have raised RMB420 million ($65 million) from their parent company and other strategic investors.
Australia's Archer agrees Healthe Care sale to China-based Luye
Archer Capital has agreed to sell Healthe Care, Australia’s third-largest private hospital group, to China-based Luye Medical Group, for $688 million. CITIC Private Equity is a shareholder in the company’s Hong Kong-listed affiliate, Luye Pharma.
Biosensors agrees to CITIC Private Equity buyout
The board of Singapore-listed medical devices manufacturer Biosensors International has accepted a buyout offer from CITIC Private Equity that values the company at approximately S$1.4 billion ($996 million).
CITIC PE seeks full ownership of Biosensors International
CITIC Private Equity has submitted a buyout offer for Biosensors International, a Singapore-listed medical devices manufacturer in which it already holds close to a 20% stake.
PE-backed China drug developer files for US IPO
BeiGene, a Chinese company backed by the likes of Hillhouse Capital and CITIC Private Equity that develops drugs to treat cancer, has filed for an IPO in the US.
ManpowerGroup teams up with CITIC PE to expand China business
CITIC Private Equity (CITIC PE) has formed a joint venture with Shanghai-based recruiting giant ManpowerGroup to expand the company's business in greater China.
CITIC PE-backed 3SBio IPO raises $711m in Hong Kong IPO
CITIC Private Equity has made a partial exit from Chinese biotech player 3SBio as the company raised HK$5.51 billion ($711 million), two years after leaving NASDAQ in a take-private deal.
GIC, BlackRock cornerstone CITIC PE-backed 3SBio's IPO
GIC Private and BlackRock have joined four other investors to cornerstone Chinese biotech pharmaceutical developer 3SBio's relisting in Hong Kong, two years after it was taken off NASDAQ by CITIC Private Equity.
China's BeiGene raises $97m from PE investors
BeiGene, a Chinese company that develops drugs to combat cancer, has raised RMB600 million ($97 million) in a funding round led by existing investors Hillhouse Capital and an undisclosed US-based life sciences-focused public investment fund.
CITIC Private Equity raises $1.3b for second US dollar fund
CITIC Private Equity has closed it second US dollar-denominated China fund with just under $1.3 billion in commitments.
CITIC PE, Beijing Enterprises Water to buy majority stake in Jin Cai
CITIC Private Equity has teamed up with Beijing Enterprises Water Group to acquire a majority stake in Jin Cai Holdings, a Hong Kong-listed cigarette packaging manufacturer that wants to enter the clean energy space.
Fortune backs Huimin's B2C-B2B switch
Huimin started out in 2012 as an online B2C platform, enabling Chinese consumers to order daily household items from small-scale supermarkets in their neighborhood. The supermarkets took care of the delivery and Huimin got a commission on each transaction....
China food-ordering platform Ele.me raises $350m
Ele.me, a Chinese online food-ordering platform, has received $350 million in a Series E round of funding from CITIC Private Equity and Sequoia Capital as well as strategic investors Tencent Holdings, JD.com and Dianping.
Chinese local supermarket O2O player gets $100m
CITIC Private Equity, Fortune Capital, GP Capital and Zhejiang Zheshang Investment Management have invested $100 million in Huimin, a Chinese B2B and B2C e-commerce platform that focuses on small-scale supermarkets.
Hillhouse, CITIC PE commit $75m to Chinese cancer drug developer
Hillhouse Capital and CITIC Private Equity have participated in a RMB450 million ($75 million) round of funding for BeiGene, a Chinese company that develops drugs to combat cancer.
CITIC PE exits Jialin Pharma via trade sale to Luye Pharma
CITIC Private Equity will exit a 10.26% stake in Beijing Jialin Pharmaceutical after Luye Pharma Group, a Chinese drug maker, agreed to buy a majority stake in its industry peer.
CITIC PE scraps plans for Biosensors takeover
CITIC Private Equity has abandoned plans for a takeover of Singapore-listed Biosensors International, although it will remain an active investor in the medical device manufacturer.
Partial exit for PE investors as Luye Pharma raises $764m
CDH Investments, CITIC Private Equity, New Horizon Capital and GIC Private have made partial exits from Luye Pharma Group as the Chinese drug maker raised HK$5.91 billion ($764 million) through its Hong Kong IPO.
Yunfeng, CITIC PE seal $320m China dairy investment
Yunfeng Capital and CITIC Private Equity have agreed to invest at least RMB2 billion ($320.5 million) in an unlisted farming subsidiary of Chinese dairy producer Inner Mongolia Yili Industrial Group.
CITIC PE considers Biosensors acquisition – update
CITIC Private Equity has held talks about potentially increasing its stake in Singapore-listed portfolio company Biosensors International, the medical device maker said on Wednesday.
CITIC PE to buy medical devices firm Biosensors - report
CITIC Private Equity is said to be looking to buy full control of its Singapore-listed portfolio company Biosensors International, a medical device maker.